Best Hospitals for Pericarditis Treatment in Bengaluru, India

Pericarditis refers to inflammation of the pericardium — the two-layered fibroserous sac encasing the heart — and is classified as acute (symptom duration <4–6 weeks), incessant (>4–6 weeks without remission), recurrent (symptom-free interval ≥4–6 weeks followed by relapse), or chronic constrictive (fibrotic obliteration of the pericardial space impairing diastolic filling). Etiologies include viral infection (most common in developed nations: Coxsackievirus B, Echovirus, SARS-CoV-2), bacterial or tuberculous infection (prevalent in South Asia and Africa), autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), post-cardiac injury syndrome (Dressler syndrome post-myocardial infarction or cardiac surgery), uremia, and malignancy. Idiopathic cases — presumed viral — account for approximately 80–85% of presentations in immunocompetent adults.

• ELIGIBLE FOR MEDICAL MANAGEMENT (NSAID + Colchicine ± Biologic Therapy):
• Adults with a confirmed diagnosis of acute idiopathic or presumed viral pericarditis (pleuritic chest pain, pericardial friction rub, ECG changes, pericardial effusion on echocardiography — at least 2 of 4 diagnostic criteria per European Society of Cardiology 2015 guidelines)
• Patients with recurrent pericarditis (≥2 documented episodes) not controlled by standard NSAIDs alone
• Autoimmune pericarditis (SLE, rheumatoid arthritis, Sjögren syndrome) with positive ANA, anti-dsDNA, or anti-CCP antibodies
• Post-cardiac injury pericarditis (post-MI Dressler syndrome, post-pericardiotomy syndrome)
• +9 more

· Transthoracic echocardiography (TTE): ventricular interdependence, septal bounce, dilated IVC, respiratory variation >25% in mitral inflow velocity

· Cardiac MRI: pericardial thickening >4 mm, late gadolinium enhancement indicating pericardial fibrosis, real-time cine imaging showing septal motion abnormalities

TIER 1 — MEDICAL MANAGEMENT (First-Line for Acute and Recurrent Pericarditis):

NSAID + Colchicine Combination Therapy (COPE/ICAP Protocol): The backbone of acute pericarditis treatment is aspirin 750–1000 mg every 8 hours (2–4 weeks, tapered) or ibuprofen 600 mg every 8 hours (2–4 weeks, tapered), combined with colchicine 0.5 mg twice daily (body weight >70 kg) or 0.5 mg once daily (<70 kg) for a minimum of 3 months. The ICAP randomized controlled trial demonstrated that colchicine addition reduces 18-month recurrence from 32.3% to 16.7% (number needed to treat: 7). Therapy is guided by hs-CRP normalization — tapering begins only after hs-CRP reaches <1 mg/L, reducing the risk of symptom rebound.

Corticosteroid Therapy: Low-to-moderate dose prednisone (0.2–0.5 mg/kg/day, maximum 25 mg/day) is indicated for autoimmune pericarditis, uremic pericarditis, post-cardiac injury pericarditis, and cases where NSAIDs are contraindicated. High-dose corticosteroids are specifically avoided for idiopathic cases; the COPE trial showed they tripled the recurrence rate compared with aspirin. Mandatory concurrent colchicine co-administration during the steroid taper reduces rebound risk.

Antituberculous Therapy (ATT) + Adjunctive Steroids: Tuberculous pericarditis is treated with standard 4-drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol for 2 months, followed by 2-drug continuation for 4 months). The IMPI trial (2014) demonstrated that adjunctive prednisolone (1–2 mg/kg/day tapering over 6 weeks) significantly reduced constrictive pericarditis development and need for pericardiectomy in HIV-negative TB pericarditis patients.

PHASE 1 — PRE-ARRIVAL & TELECONSULTATION (2–4 weeks before travel):

• GAF Healthcare coordinator receives patient's medical records, ECG, echocardiography report, cardiac MRI or CT chest, laboratory results (hs-CRP, troponin, ANA panel, IGRA/TB screen), and current medication list
• Senior cardiologist or cardiothoracic surgeon at the partner hospital reviews records within 48–72 hours and issues a detailed treatment opinion with cost estimate
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; visa letters issued by the hospital within 3–5 working days
• Patient instructed to continue all current cardiac medications during travel; anticoagulation bridging protocol provided if relevant
• Patient advised to travel with a copy of recent ECG and echo report for emergency use during transit

PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–3):